Filing Flows

Filing Flows › Altimmune (ALT) › Next earnings date

Altimmune (ALT) earnings on Nov 12, 2026: what to expect

Altimmune (ALT) is expected to report earnings on Nov 12, 2026, in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.14 (−$0.15 to −$0.12, 6 estimates), against −$0.21 and $5K a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.

Report dateNov 12, 2026
Days to go4
EPS estimate−$0.14
Beat rate75%

What to watch

Last quarter (Q4 2025) the lines that make up revenue grew like this; the report shows whether the trend holds:

Altimmune: revenue lines, growth year over year, Q4 2025Altimmune: revenue lines, growth year over year, Q4 2025Revenue+420%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.21 on revenue of $5K, against the analysts' −$0.14.

The last report

Altimmune reported revenue of $26K for the fourth quarter 2025 (+420% Y/Y), net loss $27.4M. How it makes money → · Every quarter →

Altimmune: EPS against the estimate, last 4 reportsAltimmune: EPS against the estimate, last 4 reportsEstimateReported−$0.27−$0.21Nov 25−$0.24−$0.27Mar 26−$0.25−$0.18May 26−$0.12−$0.12Aug 26
Latest (Aug 26): Estimate −$0.12, Reported −$0.12.

Altimmune's latest quarter

Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does ALT report earnings?

Altimmune is expected to report on Nov 12, 2026.

What are analysts expecting from Altimmune?

EPS of −$0.14 for the quarter.

Does Altimmune usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.